Mariner, LLC Jounce Therapeutics, Inc. Transaction History

Mariner, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.64 - $1.99 $758 - $2,358	-1,185 Reduced 0.82%	143,218 $159,000
Q3 2022 Nov 10, 2022	SELL	$2.73 - $4.92 $469 - $846	-172 Reduced 0.12%	144,403 $338,000
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $991 - $2,715	-354 Reduced 0.24%	144,575 $438,000
Q1 2022 May 13, 2022	BUY	$6.01 - $8.54 $1,081 - $1,537	180 Added 0.12%	144,929 $984,000
Q4 2021 Feb 14, 2022	SELL	$7.11 - $9.64 $33,516 - $45,442	-4,714 Reduced 3.15%	144,749 $1.21 Million
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $40 - $69	8 Added 0.01%	149,463 $1.11 Million
Q2 2021 Aug 24, 2021	BUY	$6.58 - $10.66 $381 - $618	58 Added 0.04%	149,455 $1.02 Million
Q3 2020 Nov 13, 2020	SELL	$4.58 - $10.95 $141 - $339	-31 Reduced 0.02%	149,397 $1.22 Million
Q2 2020 Aug 14, 2020	BUY	$4.17 - $7.58 $129 - $234	31 Added 0.02%	149,428 $1.03 Million
Q1 2020 May 14, 2020	BUY	$2.91 - $8.7 $434,745 - $1.3 Million	149,397 New	149,397 $710,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

Stay updated on Mariner, LLC with notifications on news.